Accepted Manuscript

Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis

Daniela Sia, Augusto Villanueva, Scott L. Friedman, Josep M. Llovet

PII: S0016-5085(16)35529-9
DOI: 10.1053/j.gastro.2016.11.048
Reference: YGAST 60876

To appear in: *Gastroenterology*
Accepted Date: 26 November 2016

Please cite this article as: Sia D, Villanueva A, Friedman SL, Llovet JM, Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis, *Gastroenterology* (2017), doi: 10.1053/j.gastro.2016.11.048.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Title: Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis

Daniela Sia[1], Augusto Villanueva[1], Scott L. Friedman[1] and Josep M. Llovet[1,2,3]

[1] Mount Sinai Liver Cancer Program (Divisions of Liver Diseases, Hematology and Medical Oncology, Department of Medicine), Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA.

[2] Liver Cancer Translational Research Laboratory, BCLC, Liver Unit, CIBEREHD, IDIBAPS, Hospital Clinic, University of Barcelona, Catalonia, Spain.

[3] Institució Catalana de Recerca i Estudis Avançats, Barcelona, Catalonia, Spain.

Grant support: DS is the recipient of the Andrea Marie Fuquay Memorial Research Fellowship (Cholangiocarcinoma Foundation). AV is the recipient of the American Association for the Study of Liver Diseases Foundation Alan Hofmann Clinical and Translational Award. SLF is supported by NIH grants DKRO156621 and AA. 020709. J.M.L. has grants from the US National Cancer Institute (NCI) (P30CA165979), the European Commission Horizon 2020 (HEP-CAR 667273–2), the Samuel Waxman Cancer Research Foundation, the Grant I+D Program (SAF2013-41027) and the Asociación Española Contra el Cáncer (AECC).

Disclosures: AV and JML are co-inventors of a patent: “Compositions, Kits, and methods for identification, assessment, prevention and therapy of hepatic disorders”.

Total Word counts: current 6543

References: current 176

Tables: 2

Figures: 5

Download English Version:

https://daneshyari.com/en/article/5658917

Download Persian Version:

https://daneshyari.com/article/5658917

Daneshyari.com